A case report of a truncated ABL1 mutation in 2 cases with Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia
Authors:
- 18 January 2024
- journal article
- case report
- Published by Springer Nature in International Journal of Hematology
- Vol. 119 (2) , 205-209
Abstract
Acquired point mutations in the ABL1 gene are widely recognized as a cause of Philadelphia chromosome-positive B cell precursor acute lymphoblastic leukemia (Ph+ B-ALL) that is resistant to tyrosine kinase inhibitors, whereas there are few reports about other types of the ABL1 mutation. Here, we report 2 cases of Ph+ B-ALL gaining a partial deletion type mutation of the ABL1 gene (Δ184-274 mutation), which resulted in truncation of the ABL1 molecule and loss of kinase activity. In both cases, the disease was refractory to multiple agents in the recurrent phase after allogeneic hematopoietic cell transplantation. This is a case report of a truncated ABL1 mutation in 2 patients with Ph+ B-ALL.Keywords
This publication has 15 references indexed in Scilit:
- A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 studyHaematologica, 2016
- Evolution of BCR/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase InhibitorPLOS ONE, 2015
- The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemiaBlood, 2011
- Chemotherapy-Phased Imatinib Pulses Improve Long-Term Outcome of Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Northern Italy Leukemia Group Protocol 09/00Journal of Clinical Oncology, 2010
- BCR-ABL Truncation due to Premature Translation Termination as a Mechanism of Resistance to Kinase InhibitorsActa Haematologica, 2009
- Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemiaLeukemia, 2008
- Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)Blood, 2007
- A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinibLeukemia, 2006
- Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemiaNature Reviews Cancer, 2005
- Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABLCell, 2003